Sequential therapy with caspofungin and fluconazole for Candida albicans infection

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 10, 2004, Pages 4056-4058

  Barchiesi, Francesco ^a   Spreghini, Elisabetta ^a   Baldassarri, Isabella ^a   Marigliano, Anna ^a   Arzeni, Daniela ^a   Giannini, Daniele ^a   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; FLUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FUNGAL STRAIN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; COLONY COUNT, MICROBIAL; DRUG THERAPY, COMBINATION; FLUCONAZOLE; HUMANS; KIDNEY; MALE; MICE; PEPTIDES, CYCLIC;

EID: 4644300973     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.10.4056-4058.2004     Document Type: Article

References (14)

1. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2002. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46:245-247.
2. Bacbmann, S. P., T. F. Patterson, and J. L. López-Ribot. 2002. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J. Clin. Microbiol. 40: 2228-2230.
3. Barchiesi, F., A. M. Schimizzi, A. W. Fothergill, G. Scalise, and M. G. Rinaldi. 1999. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. J. Clin. Microbiol. Infect. Dis. 18:302-304.
4. Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smitb, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332.
5. Como, J. A., and W. E. Dismukes. 1994. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 330:263-272.
6. Graybill, J. R., R. Bocanegra, L. K. Najvar, S. Hernandez, and R. A. Larsen. 2003. Addition of caspofungin to FLC does not improve outcome in murine candidiasis. Antimicrob. Agents Chemother. 47:2373-2375.
7. Kirkpatrick, W. R., S. Perea, B. J. Coco, and T. F. Patterson. 2002. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46:2564-2568.
8. Kontoyiannis, D. P., and R. E. Lewis. 2003. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Res. Updates 6:257-269.
9. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
10. Perea, S., G. Gonzalez, A. W. Fothergill, W. R. Kirkpatrick, M. G. Rinaldi, and T. F. Patterson. 2002. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 46:3039-3041.
11. Pfaller, M. A., D. J. Diekema, S. A. Messer, R. J. Hollis, and R. N. Jones. 2003. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother. 47:1068-1071.
12. Pfaller, M. A., R. N. Jones, G. V. Doera, A. C. Fluit, J. Verhoef, H. S. Sader, S. A. Messer, A. Houston, S. Coffman, and R. J. Hollis. 1999. International surveillance of bloodstream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn. Microbiol. Infect. Dis. 35:19-25.
13. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeast, 2nd ed. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Vazquez, J. A., M. Lynch, D. Boikov, and J. D. Sobel. 1997. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1612-1614.